Literature DB >> 26622936

Sialadenitis following low dose I-131 diagnostic thyroid scan with Thyrogen® (recombinant human thyroid stimulating hormone--thyrotropin alfa).

Marta E Gonzalez1, Thomas Jose Eluvathingal Muttikkal1, Patrice K Rehm1.   

Abstract

Salivary dysfunction and sialadenitis are well known complications of radioiodine treatment for thyroid cancer. The parotid gland is more frequently affected and the salivary gland injury is dose related. The symptoms may develop shortly after therapeutic Iodine 131(I-131) administration or months later and progress with time. The development of unilateral parotiditis following a low dose, diagnostic I-131 scan performed following Thyrogen stimulation in a patient without prior history of sialadenitis is rare in our experience, and has not been reported in the medical literature.

Entities:  

Keywords:  Iodine-131; Thyrogen; diagnostic; salivary glands; sialadenitis

Mesh:

Substances:

Year:  2015        PMID: 26622936      PMCID: PMC4638377          DOI: 10.3941/jrcr.v9i6.2220

Source DB:  PubMed          Journal:  J Radiol Case Rep        ISSN: 1943-0922


  17 in total

1.  Persistent sialadenitis after radioactive iodine therapy: report of two cases.

Authors:  S J Mandel; L Mandel
Journal:  J Oral Maxillofac Surg       Date:  1999-06       Impact factor: 1.895

Review 2.  Radioactive iodine and the salivary glands.

Authors:  Susan J Mandel; Louis Mandel
Journal:  Thyroid       Date:  2003-03       Impact factor: 6.568

3.  The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.

Authors:  Edward B Silberstein; Abass Alavi; Helena R Balon; Susan E M Clarke; Chaitanya Divgi; Michael J Gelfand; Stanley J Goldsmith; Hossein Jadvar; Carol S Marcus; William H Martin; J Anthony Parker; Henry D Royal; Salil D Sarkar; Michael Stabin; Alan D Waxman
Journal:  J Nucl Med       Date:  2012-07-11       Impact factor: 10.057

4.  Sialoendoscopic treatment for radioiodine induced sialadenitis.

Authors:  Jae Won Kim; Gil Soo Han; Seung Ho Lee; Dong Yul Lee; Young-Mo Kim
Journal:  Laryngoscope       Date:  2007-01       Impact factor: 3.325

5.  Sialoendoscopy: three years' experience as a diagnostic and treatment modality.

Authors:  O Nahlieli; A M Baruchin
Journal:  J Oral Maxillofac Surg       Date:  1997-09       Impact factor: 1.895

6.  Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer.

Authors:  K H Bohuslavizki; S Klutmann; C Bleckmann; W Brenner; S Lassmann; J Mester; E Henze; M Clausen
Journal:  Strahlenther Onkol       Date:  1999-02       Impact factor: 3.621

7.  Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication.

Authors:  P Allweiss; G D Braunstein; A Katz; A Waxman
Journal:  J Nucl Med       Date:  1984-07       Impact factor: 10.057

Review 8.  The use of radioactive iodine in thyroid carcinoma.

Authors:  A W Goolden
Journal:  Eur J Cancer Clin Oncol       Date:  1988-02

9.  Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma.

Authors:  C Alexander; J B Bader; A Schaefer; C Finke; C M Kirsch
Journal:  J Nucl Med       Date:  1998-09       Impact factor: 10.057

10.  False-positive uptake on radioiodine whole-body scintigraphy: physiologic and pathologic variants unrelated to thyroid cancer.

Authors:  Jong-Ryool Oh; Byeong-Cheol Ahn
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-07-10
View more
  3 in total

1.  Early Sialadenitis After Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Prevalence and Predictors.

Authors:  Ruba Riachy; Nisrine Ghazal; Mohamad B Haidar; Ahmad Elamine; Mona P Nasrallah
Journal:  Int J Endocrinol       Date:  2020-08-04       Impact factor: 3.257

2.  [Inflammation grading and sialoendoscopic treatment of 131I radioiodine-induced sialadenitis].

Authors:  X Li; J Z Su; Y Y Zhang; L Q Zhang; Y Q Zhang; D G Liu; G Y Yu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-06-18

3.  PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy.

Authors:  Vineet Mohan; Wouter V Vogel; Gerlof D Valk; Jan P de Boer; Marnix G E H Lam; Bart de Keizer
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.